January 6, 2021
Enzyre’s Enzypad technology was recognised by Global Health and Pharma as Best Blood Coagulation Analysis Product 2020. We are happy that the potential of the Enzypad and Enzycard technology is being acknowledged also by other experts in the field. In 2021 the Enzyre team will continue its efforts to be able to help patients around with world that will benefit from better blood coagulation analysis!
Enzyre is now preparing to raise €10M in its Series A investment round. The proceeds will be used to (a) finalize the development of the ENZYPAD en ENZYCARD Hemophilia A, (b) manufacture the portable instrument & disposable, and (c) perform studies to obtain regulatory approval in EU & US. The product will be commercialized worldwide through our pharma partner. Interested candidate investors are encouraged to contact us at firstname.lastname@example.org.Get involved